13F Holdings
中文EN

PLUR Pluri Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1158780 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.0%
TTM net income YoY-25.8%
TTM EPS YoY15.7%
Revenue 3-yr CAGR79.1%
Net income 3-yr CAGR—

Margins

Gross margin52.0%
Operating margin-2,341.1%
Net margin-1,943.9%
FCF margin-1,317.8%
EBITDA margin-2,306.0%

Returns

ROE—
ROA-96.8%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets167.1%
Debt / equity—
Current ratio0.27x
Interest coverage-36.77x

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-33.0%
Payout ratio—
Capex / revenue35.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$1.02M$1.34M$326,000$287,000$234,000
Cost of revenue$563,000$682,000$4,000$9,000—
Gross profit$453,000$654,000$322,000$278,000$234,000
R&D expense$15.09M$12.85M$12.45M$15.74M$24.61M
SG&A expense$10.30M$9.98M$10.03M$11.78M$17.45M
Operating income-$24.94M-$22.18M-$22.16M-$27.25M-$41.59M
Interest expense$932,000$873,000$866,000$843,000$887,000
Pretax income-$25.39M-$23.25M-$21.34M——
Income tax-$25,000-$5,000———
Net income-$23.82M-$22.58M-$20.89M-$28.32M-$41.24M
EBITDA-$24.43M-$21.86M-$21.91M-$26.88M-$40.54M
EPS (basic)-2.44-3.56-3.99-6.24-1.28
EPS (diluted)-2.44-3.56-3.99-6.24-1.28
Weighted avg. shares (diluted)9.74M6.34M5.24M4.58M32.19M
Balance sheet
Cash & equivalents$3.53M$7.20M$7.67M$6.26M$11.41M
Receivables————$3,000
Current assets$8.73M$22.09M$31.11M$41.41M$57.75M
PP&E, net$1.57M$1.82M$688,000$688,000$739,000
Goodwill$3.14M$3.14M———
Intangibles$2.61M$2.79M———
Total assets$24.88M$38.68M$39.53M$50.80M$68.06M
Current liabilities$32.72M$32.33M$4.45M$5.62M$6.83M
Total liabilities$42.31M$39.55M$34.11M$35.50M$35.88M
Shareholders' equity-$23.04M-$6.84M$96,000$13.36M$30.04M
Shares outstanding10.82M7.89M5.41M5.16M32.51M
Cash flow statement
Operating cash flow-$19.59M-$18.21M-$18.02M-$22.86M-$36.50M
Capital expenditure$633,000$1.62M$323,000$262,000$280,000
Free cash flow-$20.22M-$19.83M-$18.34M-$23.12M-$36.78M
Investing cash flow$9.90M$8.03M$10.58M$9.70M$11.78M
Financing cash flow$7.04M$9.53M$8.84M$8.02M$7.50M
Depreciation & amortization$511,000$316,000$253,000$362,000$1.05M
Stock-based compensation$3.73M$2.14M$2.62M$3.98M$8.91M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.